25 XP   0   0   10

Novo Nordisk A/S
Buy, Hold or Sell?

Let's analyse Novo Nordisk A/S together

PenkeI guess you are interested in Novo Nordisk A/S. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Novo Nordisk A/S. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Novo Nordisk A/S

I send you an email if I find something interesting about Novo Nordisk A/S.

Quick analysis of Novo Nordisk A/S (30 sec.)










What can you expect buying and holding a share of Novo Nordisk A/S? (30 sec.)

How much money do you get?

How much money do you get?
kr4.09
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
kr23.90
Expected worth in 1 year
kr46.03
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
kr50.63
Return On Investment
5.7%

For what price can you sell your share?

Current Price per Share
kr886.60
Expected price per share
kr727.16 - kr913.02
How sure are you?
50%

1. Valuation of Novo Nordisk A/S (5 min.)




Live pricePrice per Share (EOD)

kr886.60

Intrinsic Value Per Share

kr114.17 - kr284.67

Total Value Per Share

kr138.08 - kr308.57

2. Growth of Novo Nordisk A/S (5 min.)




Is Novo Nordisk A/S growing?

Current yearPrevious yearGrowGrow %
How rich?$15.2b$11.9b$3.3b21.7%

How much money is Novo Nordisk A/S making?

Current yearPrevious yearGrowGrow %
Making money$12b$7.9b$4b33.6%
Net Profit Margin36.0%31.4%--

How much money comes from the company's main activities?

3. Financial Health of Novo Nordisk A/S (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#5 / 1010

Most Revenue
#2 / 1010

Most Profit
#2 / 1010

Most Efficient
#41 / 1010

What can you expect buying and holding a share of Novo Nordisk A/S? (5 min.)

Welcome investor! Novo Nordisk A/S's management wants to use your money to grow the business. In return you get a share of Novo Nordisk A/S.

What can you expect buying and holding a share of Novo Nordisk A/S?

First you should know what it really means to hold a share of Novo Nordisk A/S. And how you can make/lose money.

Speculation

The Price per Share of Novo Nordisk A/S is kr886.60. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Novo Nordisk A/S.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Novo Nordisk A/S, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr23.90. Based on the TTM, the Book Value Change Per Share is kr5.53 per quarter. Based on the YOY, the Book Value Change Per Share is kr3.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr7.13 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Novo Nordisk A/S.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps2.690.3%2.690.3%1.750.2%1.680.2%1.340.2%
Usd Book Value Change Per Share0.790.1%0.790.1%0.430.0%0.380.0%0.230.0%
Usd Dividend Per Share1.020.1%1.020.1%0.800.1%0.740.1%0.620.1%
Usd Total Gains Per Share1.810.2%1.810.2%1.230.1%1.120.1%0.850.1%
Usd Price Per Share100.11-100.11-134.51-91.33-67.85-
Price to Earnings Ratio37.19-37.19-76.77-55.89-50.52-
Price-to-Total Gains Ratio55.16-55.16-109.33-84.50-84.23-
Price to Book Ratio29.21-29.21-51.06-38.32-35.91-
Price-to-Total Gains Ratio55.16-55.16-109.33-84.50-84.23-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share127.13844
Number of shares7
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share1.020.74
Usd Book Value Change Per Share0.790.38
Usd Total Gains Per Share1.811.12
Gains per Quarter (7 shares)12.707.82
Gains per Year (7 shares)50.8231.28
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1292241211121
2574492412152
38667143623283
4114891948342114
514311124510353145
617213329612464176
720015534714574207
822917839816585238
925720044918695269
10286222500207106300

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%34.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.02.00.080.0%28.06.00.082.4%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%28.00.06.082.4%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%31.03.00.091.2%

Fundamentals of Novo Nordisk A/S

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Fundamental data was last updated by Penke on 2024-04-23 15:33:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very efficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Novo Nordisk A/S.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Novo Nordisk A/S earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Novo Nordisk A/S to the Biotechnology industry mean.
  • A Net Profit Margin of 36.0% means that kr0.36 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Novo Nordisk A/S:

  • The MRQ is 36.0%. The company is making a huge profit. +2
  • The TTM is 36.0%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ36.0%TTM36.0%0.0%
TTM36.0%YOY31.4%+4.7%
TTM36.0%5Y33.3%+2.7%
5Y33.3%10Y33.1%+0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ36.0%-207.2%+243.2%
TTM36.0%-216.8%+252.8%
YOY31.4%-282.3%+313.7%
5Y33.3%-436.8%+470.1%
10Y33.1%-597.3%+630.4%
1.1.2. Return on Assets

Shows how efficient Novo Nordisk A/S is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Novo Nordisk A/S to the Biotechnology industry mean.
  • 26.6% Return on Assets means that Novo Nordisk A/S generated kr0.27 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Novo Nordisk A/S:

  • The MRQ is 26.6%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is 26.6%. Using its assets, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ26.6%TTM26.6%0.0%
TTM26.6%YOY23.0%+3.6%
TTM26.6%5Y26.9%-0.2%
5Y26.9%10Y31.8%-4.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ26.6%-13.3%+39.9%
TTM26.6%-12.8%+39.4%
YOY23.0%-11.6%+34.6%
5Y26.9%-13.8%+40.7%
10Y31.8%-15.6%+47.4%
1.1.3. Return on Equity

Shows how efficient Novo Nordisk A/S is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Novo Nordisk A/S to the Biotechnology industry mean.
  • 78.5% Return on Equity means Novo Nordisk A/S generated kr0.79 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Novo Nordisk A/S:

  • The MRQ is 78.5%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 78.5%. Using its investors money, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ78.5%TTM78.5%0.0%
TTM78.5%YOY66.5%+12.0%
TTM78.5%5Y69.3%+9.2%
5Y69.3%10Y72.1%-2.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ78.5%-16.9%+95.4%
TTM78.5%-16.1%+94.6%
YOY66.5%-14.9%+81.4%
5Y69.3%-19.3%+88.6%
10Y72.1%-20.1%+92.2%

1.2. Operating Efficiency of Novo Nordisk A/S.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Novo Nordisk A/S is operating .

  • Measures how much profit Novo Nordisk A/S makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Novo Nordisk A/S to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Novo Nordisk A/S:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY42.3%-42.3%
TTM-5Y33.9%-33.9%
5Y33.9%10Y38.4%-4.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM--238.5%+238.5%
YOY42.3%-288.4%+330.7%
5Y33.9%-486.2%+520.1%
10Y38.4%-628.4%+666.8%
1.2.2. Operating Ratio

Measures how efficient Novo Nordisk A/S is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.71 means that the operating costs are kr0.71 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Novo Nordisk A/S:

  • The MRQ is 0.712. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.712. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.712TTM0.7120.000
TTM0.712YOY0.577+0.135
TTM0.7125Y0.603+0.109
5Y0.60310Y0.588+0.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7123.235-2.523
TTM0.7123.310-2.598
YOY0.5773.838-3.261
5Y0.6035.679-5.076
10Y0.5887.823-7.235

1.3. Liquidity of Novo Nordisk A/S.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Novo Nordisk A/S is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.82 means the company has kr0.82 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Novo Nordisk A/S:

  • The MRQ is 0.823. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.823. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.823TTM0.8230.000
TTM0.823YOY0.895-0.071
TTM0.8235Y0.915-0.092
5Y0.91510Y1.092-0.178
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8233.863-3.040
TTM0.8234.169-3.346
YOY0.8955.337-4.442
5Y0.9156.122-5.207
10Y1.0926.434-5.342
1.3.2. Quick Ratio

Measures if Novo Nordisk A/S is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Novo Nordisk A/S to the Biotechnology industry mean.
  • A Quick Ratio of 0.48 means the company can pay off kr0.48 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Novo Nordisk A/S:

  • The MRQ is 0.475. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.475. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.475TTM0.4750.000
TTM0.475YOY0.761-0.286
TTM0.4755Y0.669-0.194
5Y0.66910Y0.822-0.153
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4753.504-3.029
TTM0.4753.991-3.516
YOY0.7615.371-4.610
5Y0.6696.088-5.419
10Y0.8226.395-5.573

1.4. Solvency of Novo Nordisk A/S.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Novo Nordisk A/S assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Novo Nordisk A/S to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.66 means that Novo Nordisk A/S assets are financed with 66.1% credit (debt) and the remaining percentage (100% - 66.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Novo Nordisk A/S:

  • The MRQ is 0.661. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.661. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.661TTM0.6610.000
TTM0.661YOY0.654+0.007
TTM0.6615Y0.611+0.050
5Y0.61110Y0.560+0.051
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6610.339+0.322
TTM0.6610.337+0.324
YOY0.6540.271+0.383
5Y0.6110.368+0.243
10Y0.5600.388+0.172
1.4.2. Debt to Equity Ratio

Measures if Novo Nordisk A/S is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Novo Nordisk A/S to the Biotechnology industry mean.
  • A Debt to Equity ratio of 195.1% means that company has kr1.95 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Novo Nordisk A/S:

  • The MRQ is 1.951. The company is just able to pay all its debts with equity.
  • The TTM is 1.951. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.951TTM1.9510.000
TTM1.951YOY1.890+0.061
TTM1.9515Y1.612+0.339
5Y1.61210Y1.327+0.285
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9510.392+1.559
TTM1.9510.403+1.548
YOY1.8900.335+1.555
5Y1.6120.427+1.185
10Y1.3270.461+0.866

2. Market Valuation of Novo Nordisk A/S

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Novo Nordisk A/S generates.

  • Above 15 is considered overpriced but always compare Novo Nordisk A/S to the Biotechnology industry mean.
  • A PE ratio of 37.19 means the investor is paying kr37.19 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Novo Nordisk A/S:

  • The EOD is 47.234. Based on the earnings, the company is overpriced. -1
  • The MRQ is 37.192. Based on the earnings, the company is overpriced. -1
  • The TTM is 37.192. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD47.234MRQ37.192+10.043
MRQ37.192TTM37.1920.000
TTM37.192YOY76.773-39.581
TTM37.1925Y55.893-18.701
5Y55.89310Y50.524+5.369
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD47.234-2.300+49.534
MRQ37.192-2.656+39.848
TTM37.192-2.718+39.910
YOY76.773-4.145+80.918
5Y55.893-6.258+62.151
10Y50.524-6.315+56.839
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Novo Nordisk A/S:

  • The EOD is 50.790. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 39.991. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 39.991. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD50.790MRQ39.991+10.798
MRQ39.991TTM39.9910.000
TTM39.991YOY66.468-26.476
TTM39.9915Y59.230-19.238
5Y59.23010Y53.895+5.335
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD50.790-2.974+53.764
MRQ39.991-3.306+43.297
TTM39.991-3.508+43.499
YOY66.468-5.613+72.081
5Y59.230-8.378+67.608
10Y53.895-8.873+62.768
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Novo Nordisk A/S is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 29.21 means the investor is paying kr29.21 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Novo Nordisk A/S:

  • The EOD is 37.093. Based on the equity, the company is expensive. -2
  • The MRQ is 29.207. Based on the equity, the company is expensive. -2
  • The TTM is 29.207. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD37.093MRQ29.207+7.886
MRQ29.207TTM29.2070.000
TTM29.207YOY51.060-21.853
TTM29.2075Y38.318-9.111
5Y38.31810Y35.914+2.404
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD37.0931.914+35.179
MRQ29.2072.116+27.091
TTM29.2072.097+27.110
YOY51.0602.881+48.179
5Y38.3183.550+34.768
10Y35.9143.936+31.978
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Novo Nordisk A/S compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--5.5315.5310%3.012+84%2.642+109%1.600+246%
Book Value Per Share--23.90223.9020%18.370+30%16.654+44%12.971+84%
Current Ratio--0.8230.8230%0.895-8%0.915-10%1.092-25%
Debt To Asset Ratio--0.6610.6610%0.654+1%0.611+8%0.560+18%
Debt To Equity Ratio--1.9511.9510%1.890+3%1.612+21%1.327+47%
Dividend Per Share--7.1257.1250%5.568+28%5.149+38%4.293+66%
Eps--18.77018.7700%12.218+54%11.709+60%9.348+101%
Free Cash Flow Per Share--17.45617.4560%14.112+24%11.152+57%8.825+98%
Free Cash Flow To Equity Per Share--3.8393.8390%2.715+41%2.173+77%1.048+266%
Gross Profit Margin--1.0001.0000%0.168+497%0.359+179%0.285+251%
Intrinsic Value_10Y_max--284.667--------
Intrinsic Value_10Y_min--114.175--------
Intrinsic Value_1Y_max--17.145--------
Intrinsic Value_1Y_min--9.582--------
Intrinsic Value_3Y_max--60.188--------
Intrinsic Value_3Y_min--30.570--------
Intrinsic Value_5Y_max--113.687--------
Intrinsic Value_5Y_min--53.350--------
Market Cap3002612841113.600-4%3112330815102.6003112330815102.6000%4262834800000.000-27%2919372169300.520+7%2242158761372.220+39%
Net Profit Margin--0.3600.3600%0.314+15%0.333+8%0.331+9%
Operating Margin----0%0.423-100%0.339-100%0.384-100%
Operating Ratio--0.7120.7120%0.577+23%0.603+18%0.588+21%
Pb Ratio37.093+21%29.20729.2070%51.060-43%38.318-24%35.914-19%
Pe Ratio47.234+21%37.19237.1920%76.773-52%55.893-33%50.524-26%
Price Per Share886.600+21%698.100698.1000%938.000-26%636.880+10%473.170+48%
Price To Free Cash Flow Ratio50.790+21%39.99139.9910%66.468-40%59.230-32%53.895-26%
Price To Total Gains Ratio70.049+21%55.15655.1560%109.334-50%84.496-35%84.235-35%
Quick Ratio--0.4750.4750%0.761-38%0.669-29%0.822-42%
Return On Assets--0.2660.2660%0.230+16%0.269-1%0.318-16%
Return On Equity--0.7850.7850%0.665+18%0.693+13%0.721+9%
Total Gains Per Share--12.65712.6570%8.579+48%7.791+62%5.893+115%
Usd Book Value--15280847400.00015280847400.0000%11971892400.000+28%10947471480.000+40%8831962980.000+73%
Usd Book Value Change Per Share--0.7930.7930%0.432+84%0.379+109%0.229+246%
Usd Book Value Per Share--3.4283.4280%2.634+30%2.388+44%1.860+84%
Usd Dividend Per Share--1.0221.0220%0.798+28%0.738+38%0.616+66%
Usd Eps--2.6922.6920%1.752+54%1.679+60%1.341+101%
Usd Free Cash Flow--11160105000.00011160105000.0000%9196815600.000+21%7313256600.000+53%6008546040.000+86%
Usd Free Cash Flow Per Share--2.5032.5030%2.024+24%1.599+57%1.265+98%
Usd Free Cash Flow To Equity Per Share--0.5510.5510%0.389+41%0.312+77%0.150+266%
Usd Market Cap430574681415.690-4%446308238885.713446308238885.7130%611290510320.000-27%418637969077.695+7%321525566380.776+39%
Usd Price Per Share127.138+21%100.108100.1080%134.509-26%91.329+10%67.853+48%
Usd Profit--12000142200.00012000142200.0000%7962285000.000+51%7687788720.000+56%6368078520.000+88%
Usd Revenue--33306227400.00033306227400.0000%25375203600.000+31%22914803760.000+45%19086855480.000+74%
Usd Total Gains Per Share--1.8151.8150%1.230+48%1.117+62%0.845+115%
 EOD+2 -6MRQTTM+0 -0YOY+26 -105Y+27 -910Y+27 -9

3.2. Fundamental Score

Let's check the fundamental score of Novo Nordisk A/S based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1547.234
Price to Book Ratio (EOD)Between0-137.093
Net Profit Margin (MRQ)Greater than00.360
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.475
Current Ratio (MRQ)Greater than10.823
Debt to Asset Ratio (MRQ)Less than10.661
Debt to Equity Ratio (MRQ)Less than11.951
Return on Equity (MRQ)Greater than0.150.785
Return on Assets (MRQ)Greater than0.050.266
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Novo Nordisk A/S based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.613
Ma 20Greater thanMa 50872.275
Ma 50Greater thanMa 100872.714
Ma 100Greater thanMa 200799.605
OpenGreater thanClose874.500
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Net Interest Income  -436,000233,000-203,00023,000-180,000-140,000-320,000650,000330,000



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in DKK. All numbers in thousands.

Summary
Total Assets314,486,000
Total Liabilities207,925,000
Total Stockholder Equity106,561,000
 As reported
Total Liabilities 207,925,000
Total Stockholder Equity+ 106,561,000
Total Assets = 314,486,000

Assets

Total Assets314,486,000
Total Current Assets139,646,000
Long-term Assets174,840,000
Total Current Assets
Cash And Cash Equivalents 14,392,000
Short-term Investments 15,838,000
Net Receivables 64,770,000
Inventory 31,811,000
Total Current Assets  (as reported)139,646,000
Total Current Assets  (calculated)126,811,000
+/- 12,835,000
Long-term Assets
Property Plant Equipment 90,961,000
Goodwill 4,464,000
Long Term Investments 1,663,000
Intangible Assets 55,942,000
Long-term Assets  (as reported)174,840,000
Long-term Assets  (calculated)153,030,000
+/- 21,810,000

Liabilities & Shareholders' Equity

Total Current Liabilities169,655,000
Long-term Liabilities38,270,000
Total Stockholder Equity106,561,000
Total Current Liabilities
Short Long Term Debt 5,304,000
Accounts payable 25,606,000
Other Current Liabilities 29,977,000
Total Current Liabilities  (as reported)169,655,000
Total Current Liabilities  (calculated)60,887,000
+/- 108,768,000
Long-term Liabilities
Long term Debt 15,976,000
Capital Lease Obligations Min Short Term Debt5,726,000
Long-term Liabilities Other 189,000
Long-term Liabilities  (as reported)38,270,000
Long-term Liabilities  (calculated)21,891,000
+/- 16,379,000
Total Stockholder Equity
Retained Earnings 104,839,000
Total Stockholder Equity (as reported)106,561,000
Total Stockholder Equity (calculated)104,839,000
+/- 1,722,000
Other
Capital Stock451,000
Common Stock Shares Outstanding 4,458,288
Net Debt 6,888,000
Net Invested Capital 127,841,000
Net Working Capital -30,009,000
Property Plant and Equipment Gross 138,583,000



Balance Sheet

Currency in DKK. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-311999-12-311998-12-311997-12-311996-12-311995-12-311994-12-311993-12-311992-12-311991-12-311990-12-311989-12-311988-12-311987-12-311986-12-311985-12-31
> Total Assets 
7,362,133
8,150,175
8,266,854
9,226,283
11,660,255
12,499,842
15,272,205
16,775,801
19,240,043
21,129,303
20,145,170
21,046,601
25,685,911
27,340,292
31,043,249
24,601,020
28,829,689
31,453,254
34,488,779
37,695,767
41,896,251
44,696,246
47,795,444
50,726,464
54,742,000
61,402,000
64,698,000
65,669,000
70,337,000
77,062,000
91,799,000
97,539,000
102,355,000
110,769,000
125,612,000
144,922,000
194,508,000
241,257,000
314,486,000
314,486,000241,257,000194,508,000144,922,000125,612,000110,769,000102,355,00097,539,00091,799,00077,062,00070,337,00065,669,00064,698,00061,402,00054,742,00050,726,46447,795,44444,696,24641,896,25137,695,76734,488,77931,453,25428,829,68924,601,02031,043,24927,340,29225,685,91121,046,60120,145,17021,129,30319,240,04316,775,80115,272,20512,499,84211,660,2559,226,2838,266,8548,150,1757,362,133
   > Total Current Assets 
4,289,274
4,348,963
4,192,563
4,891,538
6,392,756
6,637,202
8,487,647
10,578,571
9,201,110
13,204,066
9,634,213
9,753,085
12,842,271
13,062,860
15,931,937
12,529,114
13,825,887
13,751,952
16,301,314
17,873,797
19,529,730
20,839,413
24,332,412
29,137,092
32,666,000
37,293,000
39,591,000
40,163,000
42,058,000
46,293,000
55,140,000
59,766,000
60,080,000
59,067,000
62,456,000
65,809,000
85,595,000
108,194,000
139,646,000
139,646,000108,194,00085,595,00065,809,00062,456,00059,067,00060,080,00059,766,00055,140,00046,293,00042,058,00040,163,00039,591,00037,293,00032,666,00029,137,09224,332,41220,839,41319,529,73017,873,79716,301,31413,751,95213,825,88712,529,11415,931,93713,062,86012,842,2719,753,0859,634,21313,204,0669,201,11010,578,5718,487,6476,637,2026,392,7564,891,5384,192,5634,348,9634,289,274
       Cash And Cash Equivalents 
2,105,644
1,994,223
2,047,814
2,520,696
2,947,606
4,338,354
6,035,909
5,818,998
5,706,441
6,684,733
2,999,885
1,572,002
1,122,911
798,675
1,973,934
1,275,371
1,654,094
1,422,616
1,265,318
3,457,320
3,296,982
3,271,697
4,827,616
8,804,783
11,296,000
12,017,000
13,408,000
11,553,000
10,728,000
14,396,000
16,923,000
18,690,000
18,852,000
15,638,000
15,475,000
12,757,000
10,720,000
12,653,000
14,392,000
14,392,00012,653,00010,720,00012,757,00015,475,00015,638,00018,852,00018,690,00016,923,00014,396,00010,728,00011,553,00013,408,00012,017,00011,296,0008,804,7834,827,6163,271,6973,296,9823,457,3201,265,3181,422,6161,654,0941,275,3711,973,934798,6751,122,9111,572,0022,999,8856,684,7335,706,4415,818,9986,035,9094,338,3542,947,6062,520,6962,047,8141,994,2232,105,644
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,395,120
318,496
1,832,937
532,318
1,720,987
1,830,794
2,557,000
1,380,094
1,530,000
4,034,000
4,094,000
4,552,000
3,741,000
1,509,000
3,542,000
2,009,000
0
0
0
0
6,765,000
10,921,000
15,838,000
15,838,00010,921,0006,765,00000002,009,0003,542,0001,509,0003,741,0004,552,0004,094,0004,034,0001,530,0001,380,0942,557,0001,830,7941,720,987532,3181,832,937318,4961,395,1200000000000000000
       Net Receivables 
888,332
1,146,899
1,102,247
1,244,881
2,117,704
1,113,035
1,054,968
3,092,343
1,437,143
4,040,150
4,362,108
5,670,883
4,769,634
5,704,731
6,528,028
4,708,444
6,031,595
4,699,586
4,387,223
4,571,346
6,121,165
6,498,190
7,313,020
8,724,545
7,862,000
9,150,000
12,608,000
13,584,000
15,174,000
19,001,000
21,613,000
24,197,000
23,551,000
26,889,000
29,152,000
32,184,000
46,799,000
57,505,000
64,770,000
64,770,00057,505,00046,799,00032,184,00029,152,00026,889,00023,551,00024,197,00021,613,00019,001,00015,174,00013,584,00012,608,0009,150,0007,862,0008,724,5457,313,0206,498,1906,121,1654,571,3464,387,2234,699,5866,031,5954,708,4446,528,0285,704,7314,769,6345,670,8834,362,1084,040,1501,437,1433,092,3431,054,9681,113,0352,117,7041,244,8811,102,2471,146,899888,332
       Inventory 
1,295,298
1,208,576
1,041,892
1,125,274
1,327,447
1,185,813
1,396,769
1,667,231
2,057,526
2,479,183
2,272,220
2,510,200
2,715,528
4,641,742
4,886,780
3,970,494
4,745,078
5,909,871
6,551,272
7,210,982
7,772,807
8,396,792
9,031,324
9,633,909
10,016,000
9,689,000
9,433,000
9,543,000
9,552,000
11,357,000
12,758,000
14,341,000
15,373,000
16,336,000
17,641,000
18,536,000
19,621,000
24,388,000
31,811,000
31,811,00024,388,00019,621,00018,536,00017,641,00016,336,00015,373,00014,341,00012,758,00011,357,0009,552,0009,543,0009,433,0009,689,00010,016,0009,633,9099,031,3248,396,7927,772,8077,210,9826,551,2725,909,8714,745,0783,970,4944,886,7804,641,7422,715,5282,510,2002,272,2202,479,1832,057,5261,667,2311,396,7691,185,8131,327,4471,125,2741,041,8921,208,5761,295,298
   > Long-term Assets 
3,072,859
3,801,212
4,074,291
4,334,744
5,267,499
5,862,640
6,784,559
6,197,230
10,038,933
7,925,237
10,510,957
11,293,516
12,843,640
14,277,432
15,111,312
12,071,906
15,003,802
17,701,303
18,187,465
19,821,970
22,366,521
23,856,833
23,463,032
21,589,371
22,076,000
24,109,000
25,107,000
25,506,000
28,279,000
30,769,000
36,659,000
37,773,000
42,275,000
51,702,000
63,156,000
79,113,000
108,913,000
133,063,000
174,840,000
174,840,000133,063,000108,913,00079,113,00063,156,00051,702,00042,275,00037,773,00036,659,00030,769,00028,279,00025,506,00025,107,00024,109,00022,076,00021,589,37123,463,03223,856,83322,366,52119,821,97018,187,46517,701,30315,003,80212,071,90615,111,31214,277,43212,843,64011,293,51610,510,9577,925,23710,038,9336,197,2306,784,5595,862,6405,267,4994,334,7444,074,2913,801,2123,072,859
       Property Plant Equipment 
2,976,048
3,638,943
3,984,063
4,245,382
5,139,314
5,713,619
6,527,321
8,116,615
9,627,836
10,135,644
10,124,680
10,807,440
12,332,852
13,830,327
14,704,697
10,900,811
13,591,974
16,179,599
16,874,846
17,681,724
19,914,273
20,353,461
19,632,646
18,684,756
19,226,000
20,507,000
20,931,000
21,539,000
21,882,000
23,136,000
25,545,000
30,179,000
35,247,000
41,891,000
50,551,000
50,269,000
55,362,000
66,671,000
90,961,000
90,961,00066,671,00055,362,00050,269,00050,551,00041,891,00035,247,00030,179,00025,545,00023,136,00021,882,00021,539,00020,931,00020,507,00019,226,00018,684,75619,632,64620,353,46119,914,27317,681,72416,874,84616,179,59913,591,97410,900,81114,704,69713,830,32712,332,85210,807,44010,124,68010,135,6449,627,8368,116,6156,527,3215,713,6195,139,3144,245,3823,984,0633,638,9432,976,048
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,952
66,482
0
0
70,000
0
0
0
0
0
0
0
0
0
0
4,346,000
5,092,000
4,464,000
4,464,0005,092,0004,346,000000000000070,0000066,48216,952000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
856,000
2,150,000
2,197,000
1,762,000
1,773,000
1,808,000
1,648,000
1,441,000
1,343,000
1,663,000
1,663,0001,343,0001,441,0001,648,0001,808,0001,773,0001,762,0002,197,0002,150,000856,00000000000000000000000000000000
       Intangible Assets 
34,063
13,217
14,632
26,809
55,503
79,709
150,203
158,694
188,901
189,116
154,622
220,402
256,763
236,928
177,432
32,085
16,708
240,641
218,770
318,293
485,406
621,566
603,452
791,682
1,037,000
1,458,000
1,489,000
1,495,000
1,615,000
1,378,000
2,158,000
2,714,000
3,325,000
5,145,000
5,835,000
20,657,000
38,825,000
46,324,000
55,942,000
55,942,00046,324,00038,825,00020,657,0005,835,0005,145,0003,325,0002,714,0002,158,0001,378,0001,615,0001,495,0001,489,0001,458,0001,037,000791,682603,452621,566485,406318,293218,770240,64116,70832,085177,432236,928256,763220,402154,622189,116188,901158,694150,20379,70955,50326,80914,63213,21734,063
       Long-term Assets Other 
62,748
149,053
75,597
62,553
72,683
69,312
107,034
-2,078,079
222,197
-2,399,523
231,656
265,674
254,024
210,178
229,183
1,139,010
1,395,120
1,281,062
1,093,850
1,048,172
1,090,589
954,951
634,136
411,888
182,000
254,000
234,000
0
0
0
0
37,773,000
42,275,000
51,702,000
841,000
674,000
267,000
206,000
0
0206,000267,000674,000841,00051,702,00042,275,00037,773,0000000234,000254,000182,000411,888634,136954,9511,090,5891,048,1721,093,8501,281,0621,395,1201,139,010229,183210,178254,024265,674231,656-2,399,523222,197-2,078,079107,03469,31272,68362,55375,597149,05362,748
> Total Liabilities 
2,446,276
4,075,822
3,101,290
3,700,274
5,400,971
5,471,027
5,770,393
6,219,811
7,285,599
7,996,384
5,724,886
5,023,378
7,511,866
9,304,501
12,412,864
8,855,405
8,746,648
8,556,927
9,194,249
11,008,547
14,303,731
14,567,247
15,572,130
17,668,408
19,008,000
24,437,000
27,250,000
25,037,000
27,768,000
36,768,000
44,830,000
52,270,000
52,540,000
58,930,000
68,019,000
81,597,000
123,762,000
157,771,000
207,925,000
207,925,000157,771,000123,762,00081,597,00068,019,00058,930,00052,540,00052,270,00044,830,00036,768,00027,768,00025,037,00027,250,00024,437,00019,008,00017,668,40815,572,13014,567,24714,303,73111,008,5479,194,2498,556,9278,746,6488,855,40512,412,8649,304,5017,511,8665,023,3785,724,8867,996,3847,285,5996,219,8115,770,3935,471,0275,400,9713,700,2743,101,2904,075,8222,446,276
   > Total Current Liabilities 
1,602,763
2,196,142
2,117,924
2,727,603
3,646,679
4,167,962
3,856,193
3,423,531
3,691,044
4,578,918
3,937,037
3,673,565
5,314,657
5,485,637
6,564,993
6,416,960
5,989,825
5,959,415
6,645,875
7,331,714
10,565,470
10,159,779
10,657,576
12,987,858
13,415,000
18,476,000
20,779,000
21,638,000
24,225,000
33,689,000
40,873,000
47,436,000
47,056,000
54,164,000
58,983,000
70,273,000
99,516,000
120,940,000
169,655,000
169,655,000120,940,00099,516,00070,273,00058,983,00054,164,00047,056,00047,436,00040,873,00033,689,00024,225,00021,638,00020,779,00018,476,00013,415,00012,987,85810,657,57610,159,77910,565,4707,331,7146,645,8755,959,4155,989,8256,416,9606,564,9935,485,6375,314,6573,673,5653,937,0374,578,9183,691,0443,423,5313,856,1934,167,9623,646,6792,727,6032,117,9242,196,1421,602,763
       Short-term Debt 
63,644
62,411
1,044,940
1,260,004
1,809,794
1,719,515
1,357,148
996,700
960,134
1,455,159
725,448
117,945
1,339,962
922,871
1,145,917
818,162
827,047
566,215
975,596
510,366
1,443,611
339,036
404,006
1,337,300
418,000
1,720,000
351,000
500,000
215,000
720,000
1,073,000
229,000
1,694,000
515,000
1,474,000
7,459,000
13,684,000
1,466,000
0
01,466,00013,684,0007,459,0001,474,000515,0001,694,000229,0001,073,000720,000215,000500,000351,0001,720,000418,0001,337,300404,006339,0361,443,611510,366975,596566,215827,047818,1621,145,917922,8711,339,962117,945725,4481,455,159960,134996,7001,357,1481,719,5151,809,7941,260,0041,044,94062,41163,644
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
720,000
1,073,000
229,000
1,694,000
515,000
659,000
6,684,000
12,862,000
480,000
5,304,000
5,304,000480,00012,862,0006,684,000659,000515,0001,694,000229,0001,073,000720,00000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
653,266
739,779
2,153,977
926,838
1,029,496
2,722,230
781,533
581,312
768,104
1,005,449
978,586
969,065
863,478
1,011,072
1,070,123
1,500,347
1,712,132
1,948,434
2,284,108
2,242,000
2,906,000
3,291,000
3,859,000
4,092,000
4,950,000
4,927,000
6,011,000
5,610,000
6,756,000
6,358,000
5,717,000
8,870,000
15,587,000
25,606,000
25,606,00015,587,0008,870,0005,717,0006,358,0006,756,0005,610,0006,011,0004,927,0004,950,0004,092,0003,859,0003,291,0002,906,0002,242,0002,284,1081,948,4341,712,1321,500,3471,070,1231,011,072863,478969,065978,5861,005,449768,104581,312781,5332,722,2301,029,496926,8382,153,977739,779653,26600000
       Other Current Liabilities 
1,539,119
2,133,731
1,072,984
1,467,599
1,836,885
1,795,181
1,759,266
272,854
1,804,073
2,094,262
489,359
2,774,086
3,393,383
3,794,662
4,413,627
4,620,211
4,193,713
3,206,194
3,849,168
5,641,469
7,621,512
8,108,611
8,182,400
9,286,211
10,054,000
7,954,000
10,026,000
48,000
16,935,000
13,658,000
14,037,000
2,578,000
309,000
2,024,000
15,819,000
18,370,000
21,784,000
103,887,000
29,977,000
29,977,000103,887,00021,784,00018,370,00015,819,0002,024,000309,0002,578,00014,037,00013,658,00016,935,00048,00010,026,0007,954,00010,054,0009,286,2118,182,4008,108,6117,621,5125,641,4693,849,1683,206,1944,193,7134,620,2114,413,6273,794,6623,393,3832,774,086489,3592,094,2621,804,073272,8541,759,2661,795,1811,836,8851,467,5991,072,9842,133,7311,539,119
   > Long-term Liabilities 
843,512
1,879,680
983,365
972,671
1,754,291
1,303,066
1,914,200
2,796,281
3,594,555
3,417,466
1,787,849
1,349,813
2,197,209
3,818,864
5,847,871
2,438,445
2,756,823
2,597,512
2,548,374
3,676,833
3,738,260
4,407,468
4,914,554
4,680,550
5,593,000
5,961,000
6,471,000
3,399,000
3,543,000
3,079,000
3,957,000
4,834,000
5,484,000
4,766,000
9,036,000
11,324,000
24,246,000
36,831,000
38,270,000
38,270,00036,831,00024,246,00011,324,0009,036,0004,766,0005,484,0004,834,0003,957,0003,079,0003,543,0003,399,0006,471,0005,961,0005,593,0004,680,5504,914,5544,407,4683,738,2603,676,8332,548,3742,597,5122,756,8232,438,4455,847,8713,818,8642,197,2091,349,8131,787,8493,417,4663,594,5552,796,2811,914,2001,303,0661,754,291972,671983,3651,879,680843,512
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,079,000
3,957,000
4,834,000
5,484,000
4,766,000
6,027,000
8,427,000
11,285,000
12,513,000
0
012,513,00011,285,0008,427,0006,027,0004,766,0005,484,0004,834,0003,957,0003,079,00000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
2,000
136,000
0
0
0
0
0
0
000000136,0002,0001,000000000000000000000000000000000
> Total Stockholder Equity
4,915,858
4,074,353
5,165,564
5,526,009
6,259,285
7,028,237
9,501,220
10,555,363
11,953,764
13,131,704
14,409,200
16,014,884
18,118,584
17,970,827
18,556,455
15,745,616
20,083,040
22,896,327
25,294,531
26,687,220
27,592,520
30,128,999
32,223,314
33,058,056
35,734,000
36,965,000
37,448,000
40,632,000
42,569,000
40,294,000
46,969,000
45,269,000
49,815,000
51,839,000
57,593,000
63,325,000
70,746,000
83,486,000
106,561,000
106,561,00083,486,00070,746,00063,325,00057,593,00051,839,00049,815,00045,269,00046,969,00040,294,00042,569,00040,632,00037,448,00036,965,00035,734,00033,058,05632,223,31430,128,99927,592,52026,687,22025,294,53122,896,32720,083,04015,745,61618,556,45517,970,82718,118,58416,014,88414,409,20013,131,70411,953,76410,555,3639,501,2207,028,2376,259,2855,526,0095,165,5644,074,3534,915,858
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
754,092
754,087
753,993
710,091
707,769
709,524
713,415
706,046
672,421
649,478
636,555
620,000
600,000
580,000
560,000
550,000
530,000
520,000
510,000
500,000
490,000
480,000
470,000
462,000
456,000
0
0456,000462,000470,000480,000490,000500,000510,000520,000530,000550,000560,000580,000600,000620,000636,555649,478672,421706,046713,415709,524707,769710,091753,993754,087754,0920000000000000
   Retained Earnings 
2,869,376
2,884,868
3,115,312
3,458,997
4,057,666
4,836,822
6,127,569
7,164,450
8,542,674
9,733,089
11,013,062
12,609,375
14,593,054
14,457,038
14,689,911
12,352,648
16,415,630
19,024,831
21,149,728
22,829,290
26,924,299
28,812,409
30,699,342
33,512,738
35,146,000
36,097,000
37,111,000
39,001,000
41,137,000
41,277,000
46,816,000
46,111,000
48,977,000
53,406,000
57,817,000
63,774,000
72,004,000
80,587,000
104,839,000
104,839,00080,587,00072,004,00063,774,00057,817,00053,406,00048,977,00046,111,00046,816,00041,277,00041,137,00039,001,00037,111,00036,097,00035,146,00033,512,73830,699,34228,812,40926,924,29922,829,29021,149,72819,024,83116,415,63012,352,64814,689,91114,457,03814,593,05412,609,37511,013,0629,733,0898,542,6747,164,4506,127,5694,836,8224,057,6663,458,9973,115,3122,884,8682,869,376
   Capital Surplus 000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000
   Other Stockholders Equity 
2,046,481
1,189,485
2,050,253
2,067,012
2,201,619
2,191,414
3,373,652
3,390,914
3,411,090
3,398,615
3,396,138
3,405,508
3,525,531
2,564,804
2,565,374
2,574,805
2,556,327
2,555,046
2,572,025
2,535,368
-63,040
-33,904
-25,570
-26,746
-32,000
268,000
-243,000
-17,000
-21,000
-11,000
-10,000
-9,000
-11,000
-11,000
-10,000
-8,000
-6,000
-6,000
0
0-6,000-6,000-8,000-10,000-11,000-11,000-9,000-10,000-11,000-21,000-17,000-243,000268,000-32,000-26,746-25,570-33,904-63,0402,535,3682,572,0252,555,0462,556,3272,574,8052,565,3742,564,8043,525,5313,405,5083,396,1383,398,6153,411,0903,390,9143,373,6522,191,4142,201,6192,067,0122,050,2531,189,4852,046,481



Balance Sheet

Currency in DKK. All numbers in thousands.




Cash Flow

Currency in DKK. All numbers in thousands.




Income Statement

Currency in DKK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue232,261,000
Cost of Revenue-35,765,000
Gross Profit196,496,000196,496,000
 
Operating Income (+$)
Gross Profit196,496,000
Operating Expense-129,687,000
Operating Income102,574,00066,809,000
 
Operating Expense (+$)
Research Development32,443,000
Selling General Administrative61,598,000
Selling And Marketing Expenses0
Operating Expense129,687,00094,041,000
 
Net Interest Income (+$)
Interest Income1,069,000
Interest Expense-542,000
Other Finance Cost-197,000
Net Interest Income330,000
 
Pretax Income (+$)
Operating Income102,574,000
Net Interest Income330,000
Other Non-Operating Income Expenses0
Income Before Tax (EBT)104,674,000100,804,000
EBIT - interestExpense = -542,000
83,683,000
84,225,000
Interest Expense542,000
Earnings Before Interest and Taxes (EBIT)0105,216,000
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax104,674,000
Tax Provision-20,991,000
Net Income From Continuing Ops83,683,00083,683,000
Net Income83,683,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net1,770,000-330,000
 

Technical Analysis of Novo Nordisk A/S
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Novo Nordisk A/S. The general trend of Novo Nordisk A/S is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Novo Nordisk A/S's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Novo Nordisk A/S.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 913.02.

The bearish price targets are: 845.10 > 827.93 > 727.16.

Tweet this
Novo Nordisk A/S Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Novo Nordisk A/S. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Novo Nordisk A/S Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Novo Nordisk A/S. The current macd is 2.01110442.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Novo Nordisk A/S price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Novo Nordisk A/S. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Novo Nordisk A/S price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Novo Nordisk A/S Daily Moving Average Convergence/Divergence (MACD) ChartNovo Nordisk A/S Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Novo Nordisk A/S. The current adx is 18.26.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Novo Nordisk A/S shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Novo Nordisk A/S Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Novo Nordisk A/S. The current sar is 849.79.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Novo Nordisk A/S Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Novo Nordisk A/S. The current rsi is 54.61. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Novo Nordisk A/S Daily Relative Strength Index (RSI) ChartNovo Nordisk A/S Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Novo Nordisk A/S. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Novo Nordisk A/S price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Novo Nordisk A/S Daily Stochastic Oscillator ChartNovo Nordisk A/S Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Novo Nordisk A/S. The current cci is 79.02.

Novo Nordisk A/S Daily Commodity Channel Index (CCI) ChartNovo Nordisk A/S Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Novo Nordisk A/S. The current cmo is 12.49.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Novo Nordisk A/S Daily Chande Momentum Oscillator (CMO) ChartNovo Nordisk A/S Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Novo Nordisk A/S. The current willr is -15.30612245.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Novo Nordisk A/S Daily Williams %R ChartNovo Nordisk A/S Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Novo Nordisk A/S.

Novo Nordisk A/S Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Novo Nordisk A/S. The current atr is 20.22.

Novo Nordisk A/S Daily Average True Range (ATR) ChartNovo Nordisk A/S Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Novo Nordisk A/S. The current obv is 66,806,427.

Novo Nordisk A/S Daily On-Balance Volume (OBV) ChartNovo Nordisk A/S Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Novo Nordisk A/S. The current mfi is 49.67.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Novo Nordisk A/S Daily Money Flow Index (MFI) ChartNovo Nordisk A/S Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Novo Nordisk A/S.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Novo Nordisk A/S Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Novo Nordisk A/S based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.613
Ma 20Greater thanMa 50872.275
Ma 50Greater thanMa 100872.714
Ma 100Greater thanMa 200799.605
OpenGreater thanClose874.500
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Novo Nordisk A/S with someone you think should read this too:
  • Are you bullish or bearish on Novo Nordisk A/S? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Novo Nordisk A/S? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Novo Nordisk A/S

I send you an email if I find something interesting about Novo Nordisk A/S.


Comments

How you think about this?

Leave a comment

Stay informed about Novo Nordisk A/S.

Receive notifications about Novo Nordisk A/S in your mailbox!